Holen Sie sich die Stockscreener-App
23.12
3.02%
-0.72
Handel nachbörslich:
21.49
-1.63
-7.05%
Schlusskurs vom Vortag:
$23.84
Offen:
$23.63
24-Stunden-Volumen:
14,651
Relative Volume:
0.19
Marktkapitalisierung:
$1.25B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-143.59M
KGV:
-8.1881
EPS:
-2.8236
Netto-Cashflow:
$-119.47M
1W Leistung:
+0.57%
1M Leistung:
+28.52%
6M Leistung:
+18.32%
1J Leistung:
+24.30%
1-Tages-Spanne:
$23.12
$23.63
1-Wochen-Bereich:
$21.50
$24.41
52-Wochen-Spanne:
$11.51
$26.33
Pharvaris Nv Stock (PHVS) Company Profile
Vergleichen Sie PHVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
23.12 | 1.25B | 0 | -143.59M | -119.47M | -2.8236 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-11 | Eingeleitet | Guggenheim | Buy |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-09-25 | Eingeleitet | Wedbush | Outperform |
| 2023-08-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | Eingeleitet | Bryan Garnier | Buy |
| 2022-09-13 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2022-08-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-05-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-03-02 | Eingeleitet | BofA Securities | Neutral |
| 2021-03-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-03-02 | Eingeleitet | Oppenheimer | Outperform |
| 2021-03-02 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Pharvaris Nv Aktie (PHVS) Neueste Nachrichten
Pharvaris' $175M Equity Raise: Fueling a Strategic Leap in the HAE Market - AInvest
Pharvaris prices $175 million public offering to fund angioedema programs By Investing.com - Investing.com India
Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - The Manila Times
Pharvaris prices $175 million public offering to fund angioedema programs - Investing.com
Pharvaris Secures Massive $175M Public Offering to Advance Oral HAE Treatment Pipeline - Stock Titan
Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewswire Inc.
What analysts say about Pharvaris N.V. stockMarket-beating performance - Autocar Professional
Pharvaris N.V. Stock Analysis and ForecastExponential return rates - jammulinksnews.com
IKNA issues special CVR dividend ahead of Inmagene merger | PHVS SEC FilingForm 424B5 - Stock Titan
Pharvaris announces $150M ordinary shares offering - TipRanks
Pharvaris Announces Proposed Public Offering of Ordinary Shares - The Manila Times
Pharvaris Seeks $150M in Public Offering: Major Push for Late-Stage HAE Drug Development - Stock Titan
What drives Pharvaris N.V. stock priceTriple-digit profit margins - printweek.in
Understanding Stock Volatility in the Indian Market AI Driven Stock AlertsFree Risk Assessment Services - Autocar Professional
Is Pharvaris N.V. a good long term investmentExceptional return forecasts - jammulinksnews.com
Property Share Investment Trust (544295) Hits 52 Week HighRapid wealth creation - Autocar Professional
What drives PTON stock priceBreakout stock performance - jammulinksnews.com
What drives iShares Gold Trust stock priceHigh-yield capital appreciation - jammulinksnews.com
NSE Quality Stocks Smart Investor Club PicksHigh-velocity gains - jammulinksnews.com
Best Renewable Stocks Smart Money Stock PicksPowerful growth strategies - jammulinksnews.com
What risks could impact Pharvaris N.V. stock performanceHigh Return Stock Alerts - Newser
Pharvaris: More Convenience, More Potency, And More Potential For Future HAE Success - Seeking Alpha
How To Trade (PHVS) - news.stocktradersdaily.com
Why Pharvaris N.V. stock attracts strong analyst attentionGrowth Optimized Stock Radar - beatles.ru
How Pharvaris N.V. stock performs during market volatilityFree Investment Community - Newser
What makes Pharvaris N.V. stock price move sharplyReal Time Alert Service - Newser
Pharvaris (NASDAQ:PHVS) Reaches New 1-Year High – Should You Buy? - Defense World
Pharvaris N.V. shares fall 4.98% in after-hours after updating key study data release timeline to Q4 2025. - AInvest
Pharvaris Expects to Release Topline Data From Phase 3 Hereditary Angioedema Study in Q4 - MarketScreener
Pharvaris NV expects Rapide-3 data announcement in Q4 2025 - MarketScreener
Pharvaris Pushes Key Phase 3 HAE Drug Results to Late 2025: What This Means for Oral Treatment - Stock Titan
Pharvaris N.V. (NASDAQ:PHVS) Receives $36.20 Consensus Price Target from Brokerages - Defense World
Pharvaris Announces Key Resolutions from Annual General Meeting - TipRanks
Is Pharvaris NV technically bullish or bearish? - MarketsMojo
HAE research continues to swell post-CSL Andembry win - BioWorld MedTech
(PHVS) Trading Advice - news.stocktradersdaily.com
Pharvaris presents new data on oral angioedema treatment at EAACI By Investing.com - Investing.com UK
Finanzdaten der Pharvaris Nv-Aktie (PHVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):